Clinical Trial Update: Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating fulvestrant with exemestane endocrine therapy for postmenopausal advanced breast cancer; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Exemestane (Exemestane)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN